NCT06562647 2026-02-13SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid TumorsCell Origin Biotech (Hangzhou) Co., Ltd.Phase NA Recruiting2 enrolled
NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled